Hoffmann-la Roche Inc.

Roche Glycart Ag

Other

Bernd Mueller-beckmann

Genentech, Inc.

Roche Diagnostics Gmbh

F. Hoffmann-la Roche Ag

Valeria Lifke

Hans-Willi Krell

Guy Georges

Stefan Seeber

Georg Fertig

Birgit Bossenmaier

Sonja Offner

Christian Klein

Ekkehard Moessner

Joerg Thomas Regula

Laura Codarri-Deak

Pablo Umana

Pablo Umaña

Johann Karl

Jens Fischer

Tilman Schlothauer

Nikolaos Dimoudis

Thomas Friess

Viktor Levitski

Mario Perro

Adrian Zwick

Olaf Mundigl

Klaus Kaluza

Ulrich Goepfert

Achal Mukundrao Pashine

Bernd Bohrmann

Michael Schraeml

Stefan Dengl

Joerg Moelleken

Walter Huber

Werner Scheuer

Joerg Benz

Fiona Grueninger

Sebastian Dziadek

Barbara Weiser

Irene Kolm

Ildiko Wuensche

Alexander Lifke

Laura Codarri Deak

Christian Weilke

Oliver Ploettner

Victor Levitsky

Laurence Ozmen

Michael Schraemi

Lars Hillringhaus

Kairat Madin

Bernd Mueller-Beckmann

Tobias Schnitzer

Sebastian Fenn

Tobias Bittner

Martina Jocham

Hans Willi Krell

Achal Pashine

Verena Steffen

The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.

Bispecific antibodies specific for PD1 and TIM3

The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.

The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Anti-HER3 antibodies and uses thereof

The current invention is directed to a method for obtaining a nucleic acid encoding an immunoglobulin variable domain from a single cell comprising the following steps: &#x2014;performing a first polymerase chain reaction with three to six 5'-primer and one 3&#x2032;-primer, performing with the product of the first polymerase chain reaction a second polymerase chain reaction with thirteen to sixteen 5&#x2032;-primer and one 3&#x2032;-primer, whereby the distance of the binding locations of the primer employed in the second polymerase chain reaction is reduced compared to the first polymerase chain reaction.

Method for obtaining immunoglobulin encoding nucleic acid

The present invention relates to a method for determining the anti-tumor efficacy of monoclonal antibodies in pre-clinical rodent testings and the use of said method for the reduction of side testings.

Method for determining the anti-tumor efficacy of monoclonal antibodies

An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.

Antibodies against human IL33R and uses thereof

An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.

Use of an anti-Tau pS422 antibody for the treatment of brain diseases

The current invention is related to a method for the production of a human monoclonal antibody from a immunodeficient non-human animal, said method comprising contacting a new borne immunodeficient non-human animal with a human fetal liver stem cell (FL cell) to generate an immune transplanted non-human animal (reconstituted animal), subsequently contacting said reconstituted animal with a antigen, collecting from said reconstituted animal a human cell producing human antibody against said antigen, and isolating said antibody from said antibody producing cell.

Method for the production of antibodies

An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.

Growing community of inventors

Penzberg, Germany

Valeria Lifke